Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2022, with the report dated April 13, 2022. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of specific share transactions.
| Transaction Date | Instrument | Price (GBP) | Volume |
|---|---|---|---|
| April 8, 2022 | Ordinary Shares (ISIN: GB0009252882) | £17.4100 | 12,367.170 (CEO) + 2,018.808 (CFO) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of shares by executives following dividend reinvestment.
Management Commentary and Transaction Details
The filing discloses two separate transactions executed on April 8, 2022, on the London Stock Exchange (XLON):
- Ms. E. Walmsley (Chief Executive Officer): Acquired 12,367.170 ordinary shares at £17.4100 per share.
- Mr. I. Mackay (Chief Financial Officer): Acquired 2,018.808 ordinary shares at £17.4100 per share.
Nature of Transaction: Both acquisitions resulted from the reinvestment of dividends paid to shareholders on April 7, 2022. These shares are held in the Company's Performance Share Plan and are subject to a 2-year holding period.
Investor Verification Checklist
- Verify the dividend payment date of April 7, 2022, to confirm the reinvestment timing.
- Confirm the 2-year holding period restrictions applicable to the Performance Share Plan.
- Check the London Stock Exchange trading data for April 8, 2022, to validate the transaction price of £17.4100.
- Note that this filing contains no operational or financial performance data; refer to Form 20-F for comprehensive financial results.